FAS Wealth Partners’s Teva Pharmaceuticals TEVA Stock Holding History

FAS Wealth Partners’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$244K	Hold	7,200	–	–	0.01%	326
2026 Q1	$217K	Buy	7,200 +100	+1%	+$3.22K	0.01%	330
2025 Q4	$222K	Buy	+7,100	New	+$175K	0.01%	330
2021 Q4	–	Sell	-10,189	Closed	-$99K	–	419
2021 Q3	$99K	Hold	10,189	–	–	0.01%	312
2021 Q2	$101K	Hold	10,189	–	–	0.01%	297
2021 Q1	$118K	Hold	10,189	–	–	0.01%	273
2020 Q4	$98K	Sell	10,189 -320	-3%	-$3.07K	0.01%	270
2020 Q3	$95K	Hold	10,509	–	–	0.01%	251
2020 Q2	$130K	Sell	10,509 -354	-3%	-$4K	0.02%	230
2020 Q1	$98K	Hold	10,863	–	–	0.02%	221
2019 Q4	$106K	Hold	10,863	–	–	0.02%	209
2019 Q3	$75K	Hold	10,863	–	–	0.01%	190
2019 Q2	$100K	Hold	10,863	–	–	0.02%	190
2019 Q1	$170K	Sell	10,863 -330	-3%	-$5.82K	0.03%	186
2018 Q4	$173K	Hold	11,193	–	–	0.04%	182
2018 Q3	$241K	Hold	11,193	–	–	0.05%	165
2018 Q2	$272K	Buy	11,193 +210	+2%	+$4.28K	0.07%	154
2018 Q1	$188K	Buy	+10,983	New	+$214K	0.05%	168

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

FAS Wealth Partners's TEVA Position: Q2 2026 in Review

FAS Wealth Partners held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 7,200 shares worth $244K. The position accounts for 0.01% of the portfolio, ranked #326.

FAS Wealth Partners first reported a position in TEVA in Q1 2018 and has held it in 18 quarters since. The position peaked at $272K in Q2 2018. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

FAS Wealth Partners held 7,200 shares of Teva Pharmaceuticals worth $244K as of Q2 2026.
FAS Wealth Partners left its Teva Pharmaceuticals share count unchanged in Q2 2026.
Teva Pharmaceuticals made up 0.01% of FAS Wealth Partners's portfolio in Q2 2026, its #326 holding.
FAS Wealth Partners first reported a position in Teva Pharmaceuticals in Q1 2018 and has held it in 18 quarters since.
FAS Wealth Partners's Teva Pharmaceuticals position peaked at $272K in Q2 2018.
673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on FAS Wealth Partners's 13F filing for Q2 2026, filed 29 Jul 2026.